Insurance Approval Challenges for HPV Vaccination
New Research Offers Hope
Facing difficulties with insurance approval for HPV vaccinations? Recent findings from Maryland researchers may provide a solution for individuals seeking protection against HPV types 16 and 18. The study indicates that a single dose of either the nonvalent or bivalent HPV vaccine is just as effective as two doses.
Cost Barriers to Access
For many, the financial burden associated with multiple doses of the HPV vaccine has posed significant barriers to access. Insurance companies often hesitate to cover vaccinations for individuals over the age of 25, making this study, published in the New England Journal of Medicine in December, particularly beneficial for the underinsured and children in low-income countries.
Study Overview
The research, conducted by a team from the National Institute of Health’s immunoepidemiology unit in Maryland, involved a large randomized controlled trial in Costa Rica, where routine HPV vaccination is not available for children.
Trial Details
In this trial, 20,000 girls aged between 12 and 16 were recruited. Participants were randomly divided into three groups: one group received a single HPV shot, another received a booster in addition to the first shot, and a third group did not receive any vaccination. To prevent herd immunity from affecting the results, no more than 35% of girls in any district were allowed to participate.
Results of the Trial
Participants were screened for HPV infection every six months following their 15th birthday over a five-year period. At the conclusion of the trial, the girls who received a single dose of the vaccine showed no higher rates of HPV positivity than those who received the booster, demonstrating the efficacy of a single dose.
Further Information
For more insights, see Kreimer AR, Porras C, Liu D, et al. Noninferiority of One HPV Vaccine Dose to Two Doses. New England Journal of Medicine. 0(0). doi:10.1056/NEJMoa2506765.